Suppression of ovarian cancer cell tumorigenicity and evasion of cisplatin resistance using a truncated epidermal growth factor receptor in a rat model

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3243-3248

  Chan, John K ^a,d   Pham, Huyen ^b   Xue, Juan You ^c   Cloven, Noelle G ^b   Burger, Robert A ^b   Rose, G Scott ^b   Van Nostrand, Kristi ^b   Korc, Murray ^b   DiSaia, Philip J ^b   Fan, Hung ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Cancer Research Institute

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENICITY; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; IMMUNOCOMPETENCE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 20244368055     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3013     Document Type: Article

References (35)

1. Hoskins WJ, Perez CA, Young RC. Principles and practice of gynecologic oncology. 3rd ed. p. xxi, 1268, [1268] of plates. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 981-2.
2. DiSaia PJ, Creasman WT. Clinical gynecologic oncology. 5th ed. p. viii, 657. St. Louis: Mosby, 2002. p. 290-1.
3. Langdon SP, Miller WR, Berchuck A. Biology of female cancers. Boca Raton: CRC Press; 1997. p. 307.
4. Berchuck A, Rodriguez GC, Kamel A, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-74.
5. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9.
6. Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered type α transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A 1994;91:10217-21.
7. Hackel PO, Zwick E, Prenzel N, Ulrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999;11:184-9.
8. Wagner MT, Cao T, Lopez ME, et al. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int J Cancer 1996;68:782-7.
9. Honegger AM, Dull TJ, Felder S, et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 1987;51:199-209.
10. Eldredge ER, Korf GM, Christensen TA, Connolly DC, Getz MJ, Maihle NJ. Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor. Mol Cell Biol 1994;14:7527-34.
11. Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H, Korc M. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 2002;62:5611-7.
12. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
13. Howell SB, Isonishi S, Christen RD, Andrews PA, Mann S. Cellular pharmacologic strategies for overcoming drug resistance: potential applications to regional therapy. Eur J Surg 1991;Suppl;45-8.
14. Christen RD, Horn DK, Porter DC, et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 1990;86:1632-40.
15. Basu A, Raghunath M, Bishayee S, Das M. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol 1989;9:671-7.
16. Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992;9:383-91.
17. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-25.
18. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986;6:2895-902.
19. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
21. Tsao MS, Grisham JW. Phenotypic modulation during tumorigenesis by clones of transformed rat liver epithelial cells. Cancer Res 1987;47:1282-6.
22. Mukherjee P, Das SK. Partial characterization, progressive development and correlations of some neoplastic characters in 20-methylcholanthrene-induced transformed murine embryonal fibroblasts. Cancer Lett 1992;67:1-12.
23. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 1999;19:1938-49.
24. Christen RD, Isonishi S, Jones JA, et al. Signaling and drug sensitivity. Cancer Metastasis Rev 1994;13:175-89.
25. Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997;66:250-4.
26. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Over-expression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J Clin Invest 1992;90:1352-60.
27. Ilekis JV, Gariti J, Niederberger C, Scoccia B. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol 1997;65:36-41.
28. Rose GS, Tocco LM, Granger GA, et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 1996;175:593-9.
29. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
30. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9:79-87.
31. Langton-Webster BC, Xuan JA, Brink JR, Salomon DS. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Differ 1994;5:1367-72.
32. Nishikawa K, Rosenblum MG, Newman RA, Pandita TK, Hittelman WN, Donato NJ. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. Cancer Res 1992;52:4758-65.
33. Ogawa J, Iwazaki M, Inoue H, Koide S, Shohtsu A. Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity. Cancer 1993;71:2204-9.
34. Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol 1991;11:1454-63.
35. Redemann N, Holzmann B, von Ruden T, Wagner EF, Schlessinger J, Ulhrich A. Anti-oncogenic activity of signaling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992;12:491-8.